Genetic Counseling in Bilateral Breast Cancer

Introduction to Genetic Counseling

The National Comprehensive Cancer Network recommends that every patient with bilateral breast cancer should be offered genetic counseling, preferably before starting treatment, as bilateral disease is a strong indicator of hereditary cancer susceptibility and significantly increases the likelihood of carrying pathogenic mutations in BRCA1/2 or other cancer predisposition genes 1, 2

Bilateral breast cancer is explicitly listed as a criterion for hereditary breast and ovarian cancer (HBOC) syndrome testing in NCCN guidelines, regardless of age at diagnosis, according to the National Comprehensive Cancer Network 1
The U.S. Preventive Services Task Force identifies bilateral breast cancer as a key family history factor associated with increased likelihood of potentially harmful BRCA mutations 3, 4
Patients with bilateral breast cancer meet testing criteria even without additional family history, as two breast primaries in a single individual constitute sufficient indication for genetic evaluation, as stated by the National Comprehensive Cancer Network 1

BRCA mutation carriers with bilateral disease may benefit from risk-reducing bilateral mastectomy to address the elevated risk of additional primary tumors, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 5, 6
Platinum-based chemotherapy may be preferentially considered in BRCA mutation carriers, as recommended by the European Society for Medical Oncology 2

BRCA1/2 mutation carriers require annual surveillance with MRI and mammography with or without ultrasound for ongoing breast cancer screening, as recommended by the European Society for Medical Oncology 2
Carriers who have not undergone risk-reducing salpingo-oophorectomy need gynecologic surveillance every 6 months, according to the European Society for Medical Oncology 2
Other identified mutations (p53, PALB2, CHEK2, ATM) require gene-specific surveillance protocols, as stated by the European Society for Medical Oncology 2

Detailed pedigree analysis including first-, second-, and third-degree relatives from both maternal and paternal sides of the family should be included in the genetic counseling process, as recommended by the National Comprehensive Cancer Network 1
Education about possible test results (positive, negative, variants of uncertain significance) and their implications should be provided, according to the American Society of Clinical Oncology 7
Discussion of how results may impact medical management, surveillance, and family members should be included in the genetic counseling process, as stated by the European Society for Medical Oncology and the American Society of Clinical Oncology 2, 7
Informed consent addressing psychological implications, genetic discrimination protections, and confidentiality should be obtained, as recommended by the American Society of Clinical Oncology 7

Testing should include BRCA1/2 as primary targets, but multi-gene panel testing may be considered when hereditary cancer syndrome is suspected, according to the European Society for Medical Oncology 2
Other moderate- to high-penetrance genes (p53, PALB2, CHEK2, ATM, RAD51C, BRIP1) should be evaluated based on personal and family history, as recommended by the European Society for Medical Oncology 2
For patients with lobular breast cancer, CDH1 gene testing can be considered, as stated by the National Comprehensive Cancer Network 1

Ashkenazi Jewish women with bilateral breast cancer warrant particular attention, as they have higher prevalence of founder BRCA mutations, according to the National Comprehensive Cancer Network and the American Society of Clinical Oncology 1, 8
Every young woman with breast cancer, including those with bilateral disease, should be offered genetic counseling preferably before starting treatment, as recommended by the European Society for Medical Oncology 2
Strategies to minimize racial/ethnic and social disparities in access to genetic testing should be implemented, according to the European Society for Medical Oncology 2

Do not use general breast cancer risk assessment models (e.g., Gail model) to determine who needs genetic counseling, as these are not designed for hereditary cancer assessment, as stated by the U.S. Preventive Services Task Force 3
Genetic testing should not be performed without adequate pre-test counseling by an appropriately trained health professional, according to the European Society for Medical Oncology 2
Do not delay genetic counseling until after treatment is completed, as this misses the opportunity to inform surgical and systemic therapy decisions, as recommended by the European Society for Medical Oncology 2
Testing without formal genetic counseling is discouraged, as stated by the National Comprehensive Cancer Network 5

The presence of a predisposing mutation has implications for the patient's relatives, who may benefit from cascade genetic testing, according to the American Society of Clinical Oncology 7
Communication of genetic test results to parents and siblings should be encouraged, though little is known about factors affecting this communication, particularly in non-Caucasian populations, as stated by the European Society for Medical Oncology 2
Strategies to improve family communication about genetic results should be developed, according to the European Society for Medical Oncology 2